Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

4 results about "Exosome" patented technology

Exosomes are extracellular vesicles (EVs) that are produced in the endosomal compartment of most eukaryotic cells. The multivesicular body (MVB) is an endosome defined by intraluminal vesicles (ILVs) that bud inward into the endosomal lumen. If the MVB fuses with the cell surface (the plasma membrane), these ILVs are released as exosomes. In multicellular organisms, exosomes and other EVs are present in tissues and can also be found in biological fluids including blood, urine, and cerebrospinal fluid. They are also released in vitro by cultured cells into their growth medium. Since the size of exosomes is limited by that of the parent MVB, exosomes are generally thought to be smaller than most other EVs, from about 30 to several hundred nanometres (nm) in diameter: around the same size as many lipoproteins but much smaller than cells. Compared with EVs in general, it is unclear whether exosomes have unique characteristics or functions or can be separated or distinguished effectively from other EVs. EVs including exosomes carry markers of cells of origin and have specialized functions in physiological processes, from coagulation and intercellular signalling to waste management. Consequently, there is a growing interest in clinical applications of EVs as biomarkers and therapies alike, prompting establishment of an International Society for Extracellular Vesicles (ISEV) and a scientific journal devoted to EVs, the Journal of Extracellular Vesicles.

Method for separating exosomes in body fluid by electric field capture mechanism, and micro-fluidic chip

The invention relates to the technical field of exosome separation, and in particular relates to a method for separating exosomes in body fluid by an electric field capture mechanism, and a micro-fluidic chip. The method comprises the following steps of: (1), acquiring body fluid; (2), adding the body fluid into a liquid adding hole of the micro-fluidic chip, and polarizing particles in the mixedliquid through an external non-uniform electric field of the micro-fluidic chip; and (3), separating exosomes from other particles according to different polarization degrees of the exosomes and the other particles and the flow rate of the liquid, wherein an acute angle is formed between the opposite positive and negative electrode connecting line direction and the liquid flowing direction. Separation of the exosomes from other particles can be achieved only by adding the body fluid into the liquid adding hole by an operator; the whole method is very simple to operate; the body fluid does notneed to be treated too much in the early stage, and is non-invasive fluid; the whole early-stage treatment and separation can be completed within several minutes; the cost is relatively low; the method is very suitable for clinical popularization and application; excessive other materials do not need to be introduced; and exosome pollution is not easy to cause.
Owner:承启医学(深圳)科技有限公司

Preparation method of human adipose mesenchymal stem cell exosome for treating myocardial infarction

PendingCN111944749AExosome effect is stableDamage reliefCell dissociation methodsSkeletal/connective tissue cellsCardiac functioningCytokine
The invention provides a preparation method of human adipose mesenchymal stem cell exosome for treating myocardial infarction, and relates to the technical field of biology. The preparation method ofthe human mesenchymal stem cell exosome for treating myocardial infarction provided by the invention comprises the following steps: culturing human adipose mesenchymal stem cells, and collecting a cell culture solution; and carrying out differential centrifugation on the cell culture solution, collecting the supernatant, carrying out ultracentrifugation on the supernatant to obtain target microspheres, and then filtering, purifying and sterilizing the target microspheres to obtain the human adipose mesenchymal stem cell exosome for treating myocardial infarction. According to the present invention, the advantage is that the human adipose mesenchymal stem cell exosome is prepared by culturing human adipose mesenchymal stem cells, and the human adipose mesenchymal stem cell exosome containsvarious RNAs and cytokines, so that infarcted myocardial cells are effectively repaired, the cardiac function is enhanced, compensatory myocardial load is reduced, and heart failure is relieved; and atreatment medicine or a treatment strategy is provided for myocardial infarction.
Owner:FUJIAN MEDICAL UNIV UNION HOSPITAL

Cucumber exosome-like vesicles containing cucurbitacin B and capable of being used as anti-cancer drugs

ActiveCN112472731AGuaranteed stabilityInhibitory activityOrganic active ingredientsAntineoplastic agentsCancer cellTumor therapy
The invention discloses cucumber exosome-like vesicles containing cucurbitacin B and capable of being used as anti-cancer drugs. Cucurbitacin B can be used for inhibiting proliferation of various cancer cells, but an extraction method of cucurbitacin B is complex and time-consuming. The method of separating the cucumber exosome-like vesicles to obtain cucurbitacin B has the advantages of easinessand quickness in operation and the like, and the lipid bilayer of the exosome-like vesicles is used as a natural protective film of cucurbitacin B, so that the stability of cucurbitacin B can be maintained for a long time. Moreover, through the principle of similarity and intermiscibility, the intake rate of cells to cucurbitacin B is also improved to a certain extent due to the existence of the lipid bilayer. When the cucumber exosome-like vesicles act on human alveolar basal epithelial cells (A549 cells) of adenocarcinoma, the maximum cell activity inhibition rate of the cucumber exosome-like vesicles is twice that of a cucurbitacin B standard substance, the dosage is lower, the toxicity to normal cells and the drug resistance to cancer cells can be reduced, and the cucumber exosome-likevesicles have good anti-cancer potential and industrialization prospect, and have an important significance in the clinical tumor treatment application.
Owner:FUJIAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products